<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-02-26">February 26, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Robert</forename><surname>Fred</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Henry</forename><surname>Walter</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Ruhrlandklinik Essen</orgName>
								<orgName type="department" key="dep2">West German Lung Centre</orgName>
								<orgName type="institution" key="instit1">University Hospital Essen</orgName>
								<orgName type="institution" key="instit2">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">University Hospital Essen</orgName>
								<orgName type="institution" key="instit2">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fabian</forename><surname>Dominik Mairinger</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">University Hospital Essen</orgName>
								<orgName type="institution" key="instit2">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Institute of Pathology</orgName>
								<orgName type="department" key="dep2">Division of Molecular Pathology</orgName>
								<address>
									<settlement>Charité, Berlin, Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Robert</forename><surname>Werner</surname></persName>
							<email>robert.walter@ruhrlandklinik.uk-essen.de</email>
							<affiliation key="aff3">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">Helios Klinikum Emil von Behring</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claudia</forename><surname>Vollbrecht</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Institute of Pathology</orgName>
								<orgName type="department" key="dep2">Division of Molecular Pathology</orgName>
								<address>
									<settlement>Charité, Berlin, Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Hager</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">University Hospital Essen</orgName>
								<orgName type="institution" key="instit2">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kurt</forename><forename type="middle">Werner</forename><surname>Schmid</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">University Hospital Essen</orgName>
								<orgName type="institution" key="instit2">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jeremias</forename><surname>Wohlschlaeger</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">University Hospital Essen</orgName>
								<orgName type="institution" key="instit2">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Ev.-Luth. Diakonissenkrankenhaus Flensburg</orgName>
								<address>
									<settlement>Flensburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><forename type="middle">Christian</forename><surname>Christoph</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Medical Oncology</orgName>
								<orgName type="department" key="dep2">West German Cancer Centre</orgName>
								<orgName type="institution" key="instit1">University Hospital Essen</orgName>
								<orgName type="institution" key="instit2">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-02-26">February 26, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">D53D2E19D76D5F3AF376DE8F0880DC87</idno>
					<note type="submission">Received: January 29, 2016 Accepted: January 30, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:21+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>lung cancer</term>
					<term>neuroendocrine pulmonary tumors</term>
					<term>folic acid metabolism</term>
					<term>DNA repair</term>
					<term>NanoString nCounter</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Purpose: 25% of all lung cancer cases are neuroendocrine (NELC) including typical (TC) and atypical carcinoid (AC), large-cell neuroendocrine (LCNEC) and small cell lung cancer (SCLC).</s><s>Prognostic and predictive biomarkers are lacking.</s><s>Experimental Design: Sixty patients were used for nCounter mRNA expression analysis of the folic-acid metabolism (ATIC, DHFR, FOLR1, FPGS, GART, GGT1, SLC19A1, TYMS) and DNA-repair (ERCC1, MLH1, MSH2, MSH6, XRCC1).</s><s>Phenotypic classification classified tumors (either below or above the median expression level) with respect to the folic acid metabolism or DNA repair.</s><s>Results: Expression of FOLR1, FPGS, MLH1 and TYMS (each p&lt;0.0001) differed significantly between all four tumor types.</s><s>FOLR1 and FPGS associated with tumor differentiation (both p&lt;0.0001), spread to regional lymph nodes (FOLR1 p=0.0001 and FPGS p=0.0038),</s><s>OS and PFS (FOLR1 p&lt;0.0050 for both and FPGS p&lt;0.0004 for OS).</s><s>Phenotypic sorting revealed the Ft-phenotype to be the most prominent expression profile in carcinoids, whereas SCLC presented nearly univocal with the fT and LCNEC with fT or ft.</s><s>These results were significant for tumor subtype (p&lt;0.0001).</s><s>Conclusions: The assessed biomarkers and phenotypes allow for risk stratification (OS, PFS), diagnostic classification and enhance the biological understanding of the different subtypes of neuroendocrine tumors revealing potential new therapy options and clarifying known resistance mechanisms.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Lung cancer is still the leading cause of cancer deaths worldwide with a poor five-year survival of approximately 15% <ref type="bibr" target="#b0">[1]</ref>.</s><s>Twenty-five percent of all lung tumors belong to the group of neuroendocrine tumors <ref type="bibr" target="#b1">[2]</ref> including typical carcinoid (TC) and atypical carcinoid (AC), large-cell neuroendocrine cancer (LCNEC), and small-cell lung cancer (SCLC).</s><s>Pattern of metastasis and survival rates differ significantly between these subtypes <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b4">4]</ref>.</s></p><p><s>According to the World Health Organization (WHO) classification from 2004, LCNEC is considered as a type of non-SCLC <ref type="bibr" target="#b5">[5]</ref>.</s><s>However, it shares clinical features with SCLC such as a five-year survival of 15% up to 57% depending on the reporting source <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>Even when diagnosed at an early stage, LCNEC and SCLC show the poorest clinical outcome compared to other malignant lung tumors due to the aggressiveness of these cancer types, but the molecular characteristics of these tumors still remain largely unknown <ref type="bibr" target="#b6">[6]</ref>.</s><s>They occur almost exclusively in patients with a history of smoking and grow very rapidly, whereas lung carcinoids occur frequently in never smokers and younger patients <ref type="bibr" target="#b4">[4,</ref><ref type="bibr" target="#b7">[7]</ref><ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref>.</s></p><p><s>A platinum-based combination chemotherapy is currently the standard first-line therapy for patients with advanced Epidermal Growth Factor Receptor (EGFR) gene and Anaplastic Lymphoma Kinase (ALK) gene wild-type non-small cell lung cancer (NSCLC) <ref type="bibr" target="#b10">[10]</ref>.</s><s>The multitarget antifolate pemetrexed is used in combination with cisplatin <ref type="bibr" target="#b11">[11]</ref> or carboplatin <ref type="bibr" target="#b12">[12]</ref> in non-squamous NSCLC (including metastatic atypical carcinoids and LCNEC) <ref type="bibr" target="#b13">[13]</ref> and is often also administered after platinum-based chemotherapy as continuous maintenance therapy, as single agent after progression of first-line therapy <ref type="bibr" target="#b15">[14,</ref><ref type="bibr" target="#b16">15]</ref> or given as first-line therapy to patients who are medically unfit for platinum-based combination chemotherapy <ref type="bibr" target="#b17">[16]</ref>.</s><s>Three transporters are identified for the transport of antifolates into eukaryotic cells: the solute carrier family 19, member 1 (SLC19A1, also known as reduced folate carrier), the solute carrier family 46, member 1 (SLC46A1, also known as proto-coupled folate transporter), and the folate receptors of which folate receptor 1 (FOLR1) being the most widely studied isoform <ref type="bibr" target="#b18">[17]</ref>.</s><s>Pemetrexed inhibits folate-dependent enzymes such as thymidylate synthetase (TYMS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferases (GART) <ref type="bibr" target="#b19">[18]</ref>.</s><s>Once pemetrexed is taken up by cells, it undergoes ATP-dependent polyglutamylation catalysed by folylpolyglutamate synthase (FPGS), regulated by the reverse mechanism through gamma-glutamyltransferase 1 (GGT1).</s><s>Polyglutamylation results in more negatively charged molecules leading to higher intracellular concentration of pemetrexed <ref type="bibr" target="#b20">[19]</ref>.</s><s>Furthermore, pemetrexed shows a more than 60-fold higher activity when polyglutamylated than in its unmodified form <ref type="bibr" target="#b21">[20]</ref>.</s><s>Many of the enzymes mentioned above are involved in primary and acquired resistance mechanisms against pemetrexed <ref type="bibr" target="#b22">[21]</ref>.</s></p><p><s>Mechanism of platinum cytotoxicity includes the formation of bulky DNA adducts (generation of a chemically altered base in DNA by covalent binding of platinum <ref type="bibr" target="#b23">[22,</ref><ref type="bibr" target="#b24">23]</ref> leading to both inter-and intrastrand cross-link accumulation in DNA <ref type="bibr" target="#b24">[23,</ref><ref type="bibr" target="#b26">24]</ref>.</s><s>Finally, platinum-compounds prevent normal cell replication and trigger apoptosis <ref type="bibr" target="#b27">[25]</ref> unless adducts from genomic DNA are repaired <ref type="bibr" target="#b26">[24]</ref>.</s></p><p><s>Possible ways in which cancer cells develop a platinum-resistance include an efficient DNA-repair mechanism.</s><s>The processing of cross-links in mammalian cells is not clearly understood.</s><s>However, it is known that their processing may involve components belonging to different DNA repair pathways, including the nucleotide excision repair (NER) and the mismatch repair (MMR) pathway <ref type="bibr" target="#b28">[26]</ref>.</s><s>NER is capable of removing numerous types of DNA helix-distorting lesions induced by platinum <ref type="bibr" target="#b29">[27]</ref>.</s><s>The structure specific endonuclease excision repair crosscomplementation group 1 (ERCC1) performs an essential late step in the NER process <ref type="bibr" target="#b29">[27]</ref> and is the rate-limiting member of the NER pathway <ref type="bibr" target="#b24">[23,</ref><ref type="bibr" target="#b26">24]</ref>.</s><s>Homologous to ERCC1 in NER, X-ray repair complementing 1 (XRCC1) is the key member of the base-excision repair (BER) pathway <ref type="bibr" target="#b30">[28,</ref><ref type="bibr" target="#b31">29]</ref>.</s><s>In contrast, MMR is one of the major DNA-repair pathways, which is responsible for the repair of single-base or nucleotide mismatches and insertiondeletion loops.</s></p><p><s>MutS homologue 2 (MSH2) protein belongs to the MMR pathway and binds to platinum-induced DNA interstrand cross-links recognized by the MutSα complex, a MSH2/MSH6 heterodimer <ref type="bibr" target="#b32">[30,</ref><ref type="bibr" target="#b33">31]</ref>, thereby initiating their excision and repair <ref type="bibr" target="#b28">[26]</ref>.</s><s>Additionally, during the recombinational repair processing of interstrand crosslinks, MSH2 cooperates with several components of DNA damage repair pathways, including ERCC1 <ref type="bibr" target="#b28">[26]</ref>.</s><s>MutL homologue 1 (MLH1) protein is also a key component in the MMR pathway being involved in mismatch strand excision and subsequent repair.</s><s>In malignant pleural mesothelioma, expression levels of enzymes involved in NER and MMR pathways were correlated to each other <ref type="bibr" target="#b34">[32]</ref>.</s></p><p><s>Defects in DNA-MMR have been shown to be a mechanism of resistance to cisplatin both in vivo and in vitro <ref type="bibr" target="#b24">[23]</ref>.</s><s>Furthermore, reduced expression levels of MLH1 or MSH2 at the protein and transcriptional level have been reported in some thoracic cancers including lung cancer <ref type="bibr" target="#b28">[26,</ref><ref type="bibr" target="#b35">33,</ref><ref type="bibr" target="#b36">34]</ref>, but for neuroendocrine lung tumors a lack of prognostic and predictive biomarkers associated with response or outcome following chemotherapy limits the improvement of current systemic therapies.</s><s>A significant amount of these tumors shows a primary or acquired resistance to platinum or antifolate containing therapeutic regimes.</s></p><p><s>The main aims of our study were to find markers supporting the procedure of pathological diagnosis making in histologically difficult cases and distinguishing rare carcinoids (TC and AC) with metastatic spread, which need systemic treatment, from the less aggressive ones.</s><s>Furthermore, we aimed at the analyses of prognostic and predictive markers for aggressive subtypes of NELC.</s><s>Within this group of tumors (e.g.</s><s>LCNEC) it is of clinical importance to find markers for the correct interpretation of the biological aggressiveness to adapt treatment approaches.</s><s>Finally, we wanted to characterize the putative resistance mechanisms against platinum or antifolate containing therapeutic regimes using the NanoString nCounter system.</s><s>The nCounter technology is a hybridization-based digital detection method that can be used to analyze mRNA, miRNA and copy number variations (CNV) <ref type="bibr" target="#b37">[35]</ref><ref type="bibr" target="#b38">[36]</ref><ref type="bibr" target="#b39">[37]</ref>.</s><s>Two sequence-specific probes were used to detect the target nucleic acid covering approximately 100 nt of the gene of interest.</s><s>100 nt were identified as reproducibly detectable/amplifiable length for FFPE-derived nucleic acids <ref type="bibr" target="#b40">[38,</ref><ref type="bibr" target="#b41">39]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p><s>The mean age at date of diagnosis was 58.6 years (median age: 59 years; range 19.5-84.1).</s><s>Twentyfive patients were male gender (42%) and 27 were female (45%).</s><s>For eight patients the gender remained inconclusive.</s><s>Data about histology, TNM stages and differentiation of the tumors are summarized in Supplementary Table <ref type="table" target="#tab_0">1</ref>.</s><s>Due to the complete anonymization of all patients after merging with clinical data, lacking data could not be added.</s><s>An overview of the investigated targets and pathways is summarized in Figure <ref type="figure" target="#fig_0">1</ref>. Figure <ref type="figure" target="#fig_0">1A</ref> delineates the investigated DNA-repair members and Figure <ref type="figure" target="#fig_0">1B</ref> the folic acid pathway.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Folic acid metabolism</head><p><s>With respect to folic acid metabolism, carcinoids showed significantly higher expression than carcinomas for FOLR1 (p&lt;0.0001),</s><s>FPGS (p&lt;0.0001) and GGT1 (p=0.0289).</s><s>The opposite was found for TYMS (p&lt;0.0001).</s><s>These results are summarized in Figure <ref type="figure" target="#fig_1">2A-2D</ref>.</s><s>In line with that, FOLR1 (p&lt;0.0001),</s><s>FPGS (p&lt;0.0001),</s><s>GGT1 (p=0.0366) and TYMS (p&lt;0.0001)</s><s>associated with grade of differentiation as shown in Supplementary Figure <ref type="figure" target="#fig_0">S1A-S1D</ref>.</s><s>Furthermore, decreasing FOLR1 and FPGS expression associated significantly with increasing malignancy of the investigated NELC with respect to TNM classification (TNM stage: FOLR1 p=0.0049, spread to regional lymph nodes: FOLR1 p=0.0001,</s><s>FPGS p=0.0038).</s><s>The results are depicted in Supplementary Figure <ref type="figure" target="#fig_1">S2A</ref>-S2C.</s><s>Both showed significantly higher expression in female patients (FOLR1 p=0.0037,</s><s>FPGS p=0.0489) (data not shown).</s></p><p><s>Besides, further significant correlations for members of the folic acid pathway were found for TNM criteria and are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s></p><p><s>After identification of FOLR1 and FPGS as markers for more aggressive NELC, further correlations between folic acid pathway members were investigated.</s><s>A ratio between FOLR1 and SLC19A1 was calculated to identify the prominent uptake mechanism for each tumor subtype.</s><s>The ratio correlated significantly with tumor type (p&lt;0.0001, Figure <ref type="figure" target="#fig_2">3A</ref>) and identified FOLR1 to mediate the uptake in TC to LCNEC with an inverted ratio in SCLC, where SLC19A1 seems to mediate the folic acid uptake.</s><s>Next, the correlation between uptake (FOLR1), activation (FPGS) and utilization (TYMS) was investigated by calculating a ratio between FOLR1 and TYMS as well as FPGS and TYMS.</s><s>These ratios were calculated to determine the cellular throughput of the folic acid metabolism and associated significantly with tumor type (both p&lt;0.0001, Figure <ref type="figure" target="#fig_2">3B-3C</ref>).</s><s>A misbalance was seen between carcinoids and carcinomas.</s><s>In contrast to carcinoids, carcinomas seem to have faster utilization via TYMS than their uptake can provide.</s><s>The ratio between activation of folic acid via FPGS and inactivation via GGT1 was also tested, but reached no statistical significance (data not shown).</s></p><p><s>Furthermore, a phenotypic pathway sorting was performed.</s><s>The rationale to test for certain phenotypes was their ability to differentiate the distinct tumor types by system biological means.</s><s>The samples were classified as either having mRNA expression counts above the median (depicted by capital letters e.g.</s><s>F or T) or below median (depicted by lowercase letters e.g.</s><s>f or t). Figure <ref type="figure" target="#fig_3">4A</ref>-4B depicts the folic acid phenotypes for A) FOLR1 (median=313 counts) and TYMS (median=341 counts) and B) FPGS (median=665 counts) and TYMS.</s><s>With respect to these phenotypes, SCLC showed one predominant pattern (fT), indicating lower folic acid uptake and activation compared to their turnover rate.</s><s>In contrast, AC and TC predominantly associated with the Ft-phenotype having high uptake and activation but a considerably low utilization of folic acid.</s><s>LCNEC were more heterogenic, but two-third of all LCNEC cases associated with ft-or fT-phenotype indicating a low uptake and activation rate.</s></p><p><s>FOLR1 (p=0.0014,</s><s>HR=1) and FPGS (p&lt;0.0004,</s><s>HR=1) associated significantly with OS, but due to a hazard ratio of one they have negligible clinical relevance (shown in Figure <ref type="figure" target="#fig_4">5A-5B</ref>).</s><s>Additionally, the ratios of FOLR1 and SLC19A1 (p=0.0017,</s><s>HR=1.05),</s><s>FOLR1 and TYMS (p&lt;0.0040,</s><s>HR=1) as well as FPGS and TYMS (p&lt;0.0001,</s><s>HR=2.54, Figure <ref type="figure" target="#fig_4">5C</ref>) associated with overall survival (further data not shown due to repetitiveness to Figure <ref type="figure" target="#fig_4">5A-5C</ref>).</s></p><p><s>For PFS, FOLR1 (p=0.0049,</s><s>HR=1), FOLR1 and TYMS ratio (p=0.0200,</s><s>HR=0.26),</s><s>FOLR1 and SLC19A1 ratio (p=0.0223,</s><s>HR=0.69) as well as FPGS and TYMS ratio (p=0.0225,</s><s>HR&lt;0.01) reached statistical significance (data not shown due to repetitiveness to Figure <ref type="figure" target="#fig_4">5A-5C</ref>).</s></p><p><s>Assessment of the supposed ratios showed a high merit with clinically relevant hazard ratios compared to single marker evaluation.</s><s>Especially, the FPGS/TYMS ratio presented with a high discriminative power between poor and good prognosis and response to therapy.</s></p><p><s>The supposed phenotypes were not correlated with survival data due to the low number of cases per phenotype.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DNA-repair members</head><p><s>Members of the DNA-repair pathway correlated significantly with tumor type (ERCC1 p=0.0021,</s><s>MLH1 p&lt;0.0001,</s><s>XRCC1 p=0.0131,</s><s>MSH6 p=0.0064) (data not shown) as well as an MLH1/MSH2 ratio (p&lt;0.0010), which was calculated as stated above (depicted in Figure <ref type="figure" target="#fig_2">3D</ref>).</s><s>Furthermore, the MLH1/MSH2 phenotype was assessed as mentioned above (MLH1: median=850 counts; MSH2: median=612 counts) and reached significance with respect to tumor type (p=0.0014) as shown in Figure <ref type="figure" target="#fig_3">4C</ref>.</s><s>The M1m2-and M1M2-phenotype correlated with carcinoids (60% of TC and &gt;90% of AC), whereas carcinomas showed mostly reduced MSH1 expression (m1m2 or m1M2 in &gt;80% of LCNEC and &gt;65% of SCLC).</s><s>ERCC1 (OS: p=0.0082,</s><s>HR=1, PFS: p=0.0026,</s><s>HR=1, data not shown) associated with survival.</s><s>These and additional results are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>The mRNA level of eight genes involved in the folic acid metabolism and five genes of DNA damage repair were investigated in 60 NELC to identify subgroups that could benefit from cisplatin/pemetrexed therapy or show mechanisms of resistance against these regimens.</s><s>One reason for the lack of comprehensive studies in NELC is the rather low frequency of TC and AC in the general lung cancer patient population.</s><s>Due to the high number of lung cancer cases diagnosed at our tertiary cancer centre, a sufficient number of pulmonary TC and AC cases were available for our study.</s></p><p><s>Folate receptor 1 (the protein of the FOLR1 gene) is usually absent in SCLC and infrequently expressed in LCNEC <ref type="bibr">[44,</ref><ref type="bibr" target="#b47">45]</ref>, in accordance with our results.</s><s>Overall, low FOLR1 expression was identified as marker for more aggressive NELC and associated with shorter OS and PFS.</s><s>Although survival data for the investigated collective was limited to 35 patients for overall (OS) and 11 patients for progression-free survival (PFS) (10 and 8 events per group, respectively), we considered the results to be of interest due to their consistency to the above mentioned results.</s></p><p><s>Our group has recently reported the predictive value of FOLR1 expression in NSCLC patients receiving pemetrexed-based chemotherapy <ref type="bibr" target="#b48">[46,</ref><ref type="bibr" target="#b49">47]</ref>, indicating FOLR1 as potent biomarker in lung cancer.</s></p><p><s>We observed a significantly different TYMS gene expression between AC, TC, LCNEC, and SCLC with significantly higher expression especially in SCLC  and particularly LCNEC.</s><s>Similar results were found in retrospective studies using quantitative real-time PCR and immunohistochemistry <ref type="bibr" target="#b13">[13,</ref><ref type="bibr" target="#b50">48]</ref>.</s><s>Pemetrexed is a multitargeted antifolate that acts against TYMS, DHFR, GART and ATIC and is approved for the treatment of metastatic and unresectable non-squamous NSCLC <ref type="bibr" target="#b51">[49]</ref>.</s><s>Elevated expression of TYMS is believed to be one reason for the low efficacy of pemetrexed in SCLC <ref type="bibr" target="#b52">[50]</ref>;</s></p><p><s>similarly, squamous cell carcinomas of the lung express higher amounts of TYMS <ref type="bibr" target="#b53">[51]</ref>, which show poor response rates to pemetrexed-based therapies <ref type="bibr" target="#b51">[49,</ref><ref type="bibr" target="#b54">52]</ref>.</s><s>Putatively, low levels of FPGS might be predictive for the efficacy of pemetrexed <ref type="bibr" target="#b22">[21,</ref><ref type="bibr" target="#b51">49]</ref>.</s></p><p><s>In addition to the single marker assessment, which already revealed FOLR1 and FPGS as marker for aggressiveness and survival, the phenotypic sorting gave  additional information and allowed for more detailed risk stratification of the investigated NELC.</s><s>Phenotyping with respect to the folic acid metabolism revealed that SCLC show resistance to a pemetrexed therapy, because of the fT phenotype (low FOLR1 and FPGS, high TYMS).</s><s>A large randomized phase III clinical trial (GALES; Global Analysis of pemetrexed in SCLC Extensive Stage) had to be aborted due to futility of pemetrexed plus carboplatin regimen compared to the standard etoposide plus carboplatin approach <ref type="bibr" target="#b55">[53,</ref><ref type="bibr" target="#b56">54]</ref>, which can be explained by the supposed folic acid metabolism phenotype.</s></p><p><s>In contrast, carcinoids present predominantly with the Ft-phenotype indicating high FOLR1 and FPGS, but low TYMS gene expression levels.</s><s>Especially, FOLR1 overexpression seems to be a tumor marker in a tissuedependant manner and has gained interest for targeted therapies via antibodies (e.g.</s><s>farletuzumab) or new folic acid-drug conjugates (e.g.</s><s>vintafolide) for selective inhibition, which were tested in clinical trails <ref type="bibr" target="#b57">[55]</ref>.</s><s>Hence, the Ft-phenotype found in TC/AC provides the rationale for the administration of pemetrexed for the treatment of unresectable or metastatic TC and AC, which commonly occur at a very low frequency (1 TC and 2 AC in our study collective).</s><s>Discussions about the efficacy of cisplatin/etoposide in this setting are ongoing <ref type="bibr" target="#b58">[56]</ref> and no standard-of-care for chemotherapy exists.</s><s>Three of the investigated carcinoids showed spread to regional lymph nodes indicating an aggressive subtype of a rather low-grade tumor.</s><s>The phenotypic sorting with respect to folic acid metabolism revealed that two of them showed FOLR1 expression above the median expression (Ftphenotype) and also the third one showed a misbalance towards FOLR1 (FT-phenotype, with only &lt;3% above the median expression level of TYMS) indicating a potential benefit of an anti-folate therapy e.g. by pemetrexed or a new targeted therapy concept (vintafolide, farletuzumab) <ref type="bibr" target="#b57">[55]</ref>.</s><s>Of note, AC, TC and LCNEC belong to NSCLC <ref type="bibr" target="#b5">[5]</ref>, although of their neuroendocrine differentiation, and pemetrexed is approved for non-squamous NSCLC <ref type="bibr" target="#b51">[49]</ref>, making pemetrexed a reasonable therapy option.</s></p><p><s>With respect to the DNA-repair members, the lowest MLH1 expression was found in LCNEC.</s><s>A comparison of MLH1 expression between pulmonary adenocarcinomas, squamous cell carcinomas and LCNEC was reported showing normal MLH1 expression (compared to normal bronchial mucosa) in 13 out of 18 LCNEC specimens and reduced expression in the remaining 5 specimens <ref type="bibr" target="#b60">[57]</ref>.</s><s>Reduction of MLH1 expression was reported to be a driver of platin resistance <ref type="bibr" target="#b61">[58,</ref><ref type="bibr" target="#b62">59]</ref> indicating that highgrade NELC are more prone to platin resistance than carcinoids, according to our results.</s><s>Elevated expression of MSH2 was identified to contribute to such resistance mechanism <ref type="bibr" target="#b62">[59]</ref>.</s><s>The phenotypic sorting with respect to DNA repair revealed the negative prognostic m1m2-and Approximately 90% of all TC and more than 75% of AC belong to the Ft-or FT-phenotype indicating high expression of FOLR1 and FPGS, but low TYMS predestining them for a pemetrexed treatment.</s><s>LCNEC present in equal shares ft-and fT-phenotypes making them resistant against pemetrexed.</s><s>In &gt;95% of SCLC the fT-phenotype was present revealing why pemetrexed therapy is no option for this entity.</s><s>With respect to DNA repair, LCNEC and SCLC present with the m1m2-and m1M2-phenotype in &gt;65% of all cases, which is linked to platin resistance.</s><s>m1M2-phenotype to be associated with high-grade tumors indicating overall reduced MLH1 expression in high-grade NELC.</s></p><p><s>The NanoString nCounter system is a reproducible, sensitive and specific method that can detect even low abundance mRNAs that are below the detection limit of microarrays <ref type="bibr" target="#b37">[35]</ref>.</s><s>Additionally, the method is able to allow analysis of FFPE tissue yielding similar results as using fresh-frozen tissue for RNA investigations <ref type="bibr" target="#b63">[60]</ref>.</s><s>Due to the advanced stage at diagnosis, usually biopsies were collected from LCNEC and SCLC patients yielding rather small specimens and a huge part of these specimens was used for RNA extraction.</s><s>We decided not to perform RT-PCR, because the NanoString nCounter system has already been validated in several publications <ref type="bibr" target="#b37">[35,</ref><ref type="bibr" target="#b38">36,</ref><ref type="bibr" target="#b41">39,</ref><ref type="bibr" target="#b43">41,</ref><ref type="bibr" target="#b63">60]</ref>.</s><s>A weakness of our current work is the lack of immunohistochemical investigations, which use antibodies specifically directed against functionally active enzymes.</s><s>Discussions about their specificity and particularly about their ability to detect functionally active enzymes are ongoing <ref type="bibr" target="#b64">[61]</ref>.</s><s>Besides, validation of the nCounter technology by other techniques (e.g.</s><s>qPCR, IHC, blotting etc.) may not be important as NanoString has launched an FDA-and CE-IVD-approved mRNA expression test (Prosigna) for the investigation of the PAM50-gene signature in FFPE-derived samples from breast cancer patients <ref type="bibr" target="#b65">[62]</ref>.</s></p><p><s>To summarize, gene expression of enzymes involved in folic acid metabolism as well as repair of DNA damage showed strong associations with the tumor entity in neuroendocrine tumors of the lung.</s><s>Associations between the differentiation of these tumors, lymph node invasion and prognostic or predictive biomarkers could be identified.</s><s>The supposed multi-marker assessment (phenotypic sorting) and system biological analysis can enhance risk stratification and provide additional guidance for therapy identification, also beyond lung cancer of the neuroendocrine subtype.</s><s><ref type="figure">and C</ref>. FPGS/TYMS ratio.</s><s>The single-fractional curves on the left side display the expression-dependant survival above the chosen threshold (FOLR1=110 mRNA counts, FPGS=590 mRNA counts, and FPGS/TYMS ratio=median=0.4979,</s><s>empirically determined), whereas the single-fractional curves in the middle depict the survival curve for expression above the mentioned expression.</s><s>Both curves contain the 95% confidence interval, which is pictured by the dashed lines.</s><s>The combined survival curve is shown on the right side and contains the p-value, which was obtained by using the COXPH-model and is rounded to the fourth decimal place.</s><s>The x-axis is a time line and the y-axis displays the number events in a percentaged scale.</s><s>Higher expression of FOLR1 and FPGS correlated with prolonged survival and a higher FPGS expression than TYMS expression was identified as further positive prognostic marker.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>For this biomarker exploratory study, sixty different formalin-fixed paraffin-embedded (FFPE) tumor specimens representative for each tumor entity (16 TC, 13 AC, 16 LCNEC, and 15 SCLC) were used for mRNA expression analysis.</s><s>The initial diagnosis was made according to the WHO Classification Of Tumors <ref type="bibr" target="#b5">[5]</ref>, based on immunohistochemistry and confirmed by two experienced pathologists (JWO, THA).</s><s>Only tumor specimens with a minimum of infiltration by lymphocytes or stromal cells and which were received from patients before any chemo-or radiotherapy were considered.</s><s>The study included only patients with pulmonary neuroendocrine tumors, who were treated at the West German Cancer Centre between 2005 and 2011.</s><s>Clinicopathological data included age, gender, histology, stages (Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s><s>Tumor staging was based on the tumor, node, and metastasis (TNM) staging system (7 th edition) as proposed by the International Association for the Study of Lung Cancer (IASLC) <ref type="bibr" target="#b42">[40]</ref>.</s><s>Progression-free survival (PFS) was calculated from the date of diagnosis until progression or loss to follow-up during any treatment.</s><s>Overall survival (OS) was defined as the time between diagnosis until the date of death, or the date of last follow-up.</s><s>Patients were censored at the last follow-up if still alive or lost to follow-up.</s><s>Surveillance of PFS/OS for this study was stopped on August 31, 2014.</s><s>The retrospective study was approved by the Ethics Committee of the Medical Faculty of the University Duisburg-Essen (identifier: 13-5382-BO).</s><s>The investigation conforms to the principles outlined in the declaration of Helsinki.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RNA extraction and RNA integrity assessment</head><p><s>According to the manufacturer's recommendations, three to five FFPE sections with a thickness of 4 μm per slide were deparaffinised with xylene prior to RNA extraction using the RNeasy FFPE kit (Qiagen, Venlo, Netherlands).</s><s>RNA concentration was measured using a Nanodrop 1000 instrument (Thermo Fisher Scientific, WA, USA).</s><s>RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA) at the NanoString nCounter Core Facility at the University of Heidelberg (Heidelberg, Germany).</s><s>Smear analysis was performed using the Agilent 2100 expert software to determine the proportion of RNA ≥300 nt within a given sample.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NanoString CodeSet design and expression quantification</head><p><s>Important genes of the folic acid metabolism (eight genes: ATIC, DHFR, FOLR1, FPGS, GART, GGT1, SLC19A1, TYMS) and DNA damage repair (five genes: ERCC1, MLH1, MSH2, MSH6, XRCC1) were included in the CodeSet.</s><s>The complete CodeSet was designed to contain a total of 91 genes with different signature genes for each tumor entity and some results have been published previously <ref type="bibr" target="#b38">[36,</ref><ref type="bibr" target="#b41">39,</ref><ref type="bibr" target="#b43">41]</ref>.</s><s>Three potential reference genes (ACTB, GAPDH, and HPRT1) were also included in the CodeSet for biological normalization purposes <ref type="bibr" target="#b40">[38,</ref><ref type="bibr" target="#b44">42]</ref>.</s><s>Probe sets for each gene in the CodeSet were designed and synthesized at NanoString Technologies (Seattle, WA, USA).</s><s>Total RNA (100 ng) including mRNA and miRNA was measured at the NanoString nCounter Core Facility at the University of Heidelberg, Germany.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NanoString data processing and statistical analysis</head><p><s>Raw NanoString counts for each gene were subjected to a technical normalization taking positive and negative probes into account.</s><s>A background correction was carried out by subtracting average negative-control counts plus two-times standard deviation from each target counts.</s><s>After this procedure a biological normalization using reference genes was performed by choosing appropriate reference genes based on the geNorm algorithm <ref type="bibr" target="#b45">[43]</ref>.</s><s>All statistical analyses were calculated with the R statistical programming environment (v3.1.1.).</s><s>For dichotomous factors such as gender and expression level the Wilcoxon Mann-Whitney rank sum test was applied.</s><s>For variables with more than two categories the Kruskal-Wallis test was done.</s><s>Associations between gene expression of tested genes and associations between gene expression and TNM-criteria were analyzed by Spearman's rank correlation test.</s><s>Two-dimensional contingency tables were analyzed using the Pearson's Chisquared test.</s></p><p><s>Kaplan-Meier analysis was done for the assessment of associations between gene expression and survival data.</s><s>Significant survival differences between groups were verified by COXPH-model using a confidence interval of 95% for the Wald-test, likelihood-ratio test and Score (logrank) test.</s><s>The level of statistical significance was defined as p≤0.05.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc><div><p><s>Figure 1: Sketch of the investigated DNA repair members and folic acid pathway.</s><s>The upper line A. depicts the DNA damage response members that were investigated and their mode of action (blue octahedrons).</s><s>The lower line B. presents a summary of the folic acid metabolism pathway.</s><s>Yellow spheres represent mRNAs that were assessed via the nCounter technology.</s><s>Grey spheres were not assessed.</s><s>A cell membrane is pictured by a pale blue line associated with two spheres, which represent transmembrane proteins.</s><s>Triangles depict conjugates of folic acid that is substrate/product of the mentioned enzymes.</s><s>Blue octahedrons represent the final deployment of the modified folic acids.</s></p></div></figDesc><graphic coords="4,111.98,125.95,389.04,528.36" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 :</head><label>2</label><figDesc><div><p><s>Figure 2: Correlation of FOLR1, FPGS, GGT1 and TYMS mRNA expression and tumor subtype.</s><s>Associations between the tumor subtype and gene expression of A. FOLR1, B. FPGS, (upper line), C. GGT1 and D. TYMS (lower line) are pictured as boxplots.</s><s>On the x-axis the four investigated tumor subtypes are depicted.</s><s>The y-axis shows the mRNA counts measured by the nCounter technology.</s><s>The p-value is based on a Kruskal-Wallis rank sum test and is rounded to the fourth decimal place.</s><s>FOLR1 and GGT1 expression decreased with increasing malignancy from TC to SCLC.</s><s>The opposite was found for TYMS.</s><s>FPGS showed higher expression in carcinoids than in carcinomas.</s></p></div></figDesc><graphic coords="5,63.57,310.61,485.87,347.39" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 :</head><label>3</label><figDesc><div><p><s>Figure 3: Ratios of members of folic acid metabolism and DNA repair discriminate different subtypes of pulmonary neuroendocrine tumors.</s><s>The natural logarithmical scaled ratios for A. FOLR1/SLC19A1, B. FOLR1/TYMS, C. FPGS/TYMS and D.MLH1/MSH2 are shown (y-axis) in correlation to the four investigated tumor subtypes (x-axis).</s><s>The p-value is based on a Kruskal-Wallis rank sum test and is rounded to the fourth decimal place.</s><s>A red line depicts the x-axis at the zero-point.</s><s>The ratio depicted in A. differentiate SCLC from the other entities, indicating that SCLC use SLC19A1 as predominant receptor for uptake of folic acids.</s><s>The ratios in B. and C. identify higher FOLR1 and FPGS, but lower TYMS expression in carcinoids.</s><s>In carcinomas, higher TYMS expression is found, whereas FOLR1 and FPGS are considerably reduced.</s></p></div></figDesc><graphic coords="8,76.10,403.29,460.80,233.63" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 :</head><label>4</label><figDesc><div><p><s>Figure 4: Phenotypic sorting reveals differential expression patterns between carcinoids and carcinomas.</s><s>The phenotypic distribution for A. FOLR1/TYMS, B. FPGS/TYMS and C. MLH1/MSH2 is shown for each tumor entity.</s><s>Phenotypic sorting was performed by classifying expression below the median with a lowercase letter (f, t, m1, m2) and expression above the median with a capital letter (F, T, M1, M2): (FOLR1 (median=313 counts), FPGS (median=665 counts), TYMS (median=341 counts), MLH1 (median=850 counts), MSH2 (median=612 counts)).</s><s>A. and B. show the folic acid phenotypes, whereas C. depicts the DNA repair phenotype.</s><s>On the x-axis the four investigated tumor types are displayed.</s><s>The y-axis depicts the percentaged distribution of each phenotype.</s><s>The p-value is based on a Pearson's Chi-squared test and is rounded to the fourth decimal place.Approximately 90% of all TC and more than 75% of AC belong to the Ft-or FT-phenotype indicating high expression of FOLR1 and FPGS, but low TYMS predestining them for a pemetrexed treatment.</s><s>LCNEC present in equal shares ft-and fT-phenotypes making them resistant against pemetrexed.</s><s>In &gt;95% of SCLC the fT-phenotype was present revealing why pemetrexed therapy is no option for this entity.</s><s>With respect to DNA repair, LCNEC and SCLC present with the m1m2-and m1M2-phenotype in &gt;65% of all cases, which is linked to platin resistance.</s></p></div></figDesc><graphic coords="9,59.10,311.43,494.40,257.34" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5 :</head><label>5</label><figDesc><div><p><s>Figure 5: Kaplan-Meier curves for mRNA-expression dependant overall survival.</s><s>Each line presents the single-fractional and combined Kaplan-Meier curves for A. FOLR1, B. FPGSand C. FPGS/TYMS ratio.</s><s>The single-fractional curves on the left side display the expression-dependant survival above the chosen threshold (FOLR1=110 mRNA counts, FPGS=590 mRNA counts, and FPGS/TYMS ratio=median=0.4979,</s><s>empirically determined), whereas the single-fractional curves in the middle depict the survival curve for expression above the mentioned expression.</s><s>Both curves contain the 95% confidence interval, which is pictured by the dashed lines.</s><s>The combined survival curve is shown on the right side and contains the p-value, which was obtained by using the COXPH-model and is rounded to the fourth decimal place.</s><s>The x-axis is a time line and the y-axis displays the number events in a percentaged scale.</s><s>Higher expression of FOLR1 and FPGS correlated with prolonged survival and a higher FPGS expression than TYMS expression was identified as further positive prognostic marker.</s></p></div></figDesc><graphic coords="10,59.20,356.63,480.00,251.52" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 : Summary of the statistical tests performed and obtained significances Statistical Test</head><label>1</label><figDesc></figDesc><table><row><cell>Tumor Type</cell><cell>Kruskal-Wallis rank sum test</cell><cell>Chi-square</cell></row><row><cell>FOLR1</cell><cell>p&lt;0.0001</cell><cell>27.16</cell></row><row><cell>FPGS</cell><cell>p&lt;0.0001</cell><cell>29.24</cell></row><row><cell>GGT1</cell><cell>p=0.0289</cell><cell>9.03</cell></row><row><cell>TYMS</cell><cell>p&lt;0.0001</cell><cell>23.69</cell></row><row><cell>FOLR1/TYMS Ratio</cell><cell>p&lt;0.0001</cell><cell>36.44</cell></row><row><cell>FOLR1/SLC19A1 Ratio</cell><cell>p&lt;0.0001</cell><cell>24.94</cell></row><row><cell>FPGS/TYMS Ratio</cell><cell>p&lt;0.0001</cell><cell>32.77</cell></row><row><cell>FPGS/GGT1 Ratio</cell><cell>p=0.1</cell><cell></cell></row><row><cell>ERCC1</cell><cell>p=0.0021</cell><cell>14.69</cell></row><row><cell>MLH1</cell><cell>p&lt;0.0001</cell><cell>16.61</cell></row><row><cell>XRCC1</cell><cell>p=0.0131</cell><cell>10.75</cell></row><row><cell>MSH6</cell><cell>p=0.0064</cell><cell>12.29</cell></row><row><cell>MLH1/MSH2 Ratio</cell><cell>p&lt;0.0010</cell><cell>16.34</cell></row><row><cell></cell><cell>Pearson's Chi-squared test</cell><cell>X-squared</cell></row><row><cell>FOLR1/TYMS Phenotype</cell><cell>p&lt;0.0001</cell><cell>47.34</cell></row><row><cell>FGPS/TYMS Phenotype</cell><cell>p&lt;0.0001</cell><cell>47.32</cell></row><row><cell>MLH1/MSH2 Phenotype</cell><cell>p=0.0014</cell><cell>27.10</cell></row><row><cell>Grade of Differentiation</cell><cell>Spearman's rank correlation rho</cell><cell>rho</cell></row><row><cell>FOLR1</cell><cell>p&lt;0.0001</cell><cell>-0.6421</cell></row><row><cell>FPGS</cell><cell>p&lt;0.0001</cell><cell>-0.6501</cell></row><row><cell>TYMS</cell><cell>p&lt;0.0001</cell><cell>0.6329</cell></row><row><cell>GGT1</cell><cell>p=0.0366</cell><cell>-0.2825</cell></row><row><cell>ERCC1</cell><cell>p&lt;0.007</cell><cell>-0.3599</cell></row><row><cell>MLH1</cell><cell>p=0.0046</cell><cell>-0.3766</cell></row><row><cell>MSH6</cell><cell>p=0.0210</cell><cell>0.3105</cell></row><row><cell>Tumor Stage</cell><cell>Spearman's rank correlation rho</cell><cell>rho</cell></row><row><cell>FOLR1</cell><cell>p=0.0049</cell><cell>-0.4076</cell></row><row><cell>ERCC1</cell><cell>p=0.0147</cell><cell>-0.3575</cell></row><row><cell>MLH1</cell><cell>p=0.0214</cell><cell>-0.3383</cell></row><row><cell>XRCC1</cell><cell>p=0.0226</cell><cell>-0.3357</cell></row><row><cell></cell><cell></cell><cell>(Continued )</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Progression-Free Survival (PFS) Score (logrank) test Hazard Ratio</head><label></label><figDesc></figDesc><table><row><cell></cell><cell>Statistical Test</cell><cell></cell></row><row><cell>Spread to Lymph Nodes (N-Stage)</cell><cell>Spearman's rank correlation rho</cell><cell>rho</cell></row><row><cell>FOLR1</cell><cell>p=0.0001</cell><cell>-0.5192</cell></row><row><cell>FPGS</cell><cell>p=0.0038</cell><cell>-0.4021</cell></row><row><cell>MLH1</cell><cell>p=0.0111</cell><cell>-0.3562</cell></row><row><cell>Gender</cell><cell>Exact Wilcoxon Mann-Whitney Rank Sum Test</cell><cell>Z-value</cell></row><row><cell>FOLR1</cell><cell>p=0.0037</cell><cell>2.87</cell></row><row><cell>FPGS</cell><cell>p=0.0489</cell><cell>1.97</cell></row><row><cell>ERCC1</cell><cell>p=0.0408</cell><cell>2.04</cell></row><row><cell>MLH1</cell><cell>p=0.0308</cell><cell>2.15</cell></row><row><cell>XRCC1</cell><cell>p=0.0246</cell><cell>2.24</cell></row><row><cell>Overall Survival (OS)</cell><cell>Likelihood ratio test</cell><cell>Hazard Ratio</cell></row><row><cell>Data for 35 patients (10 events)</cell><cell></cell><cell></cell></row><row><cell>FOLR1</cell><cell>p=0.0014</cell><cell>1.00</cell></row><row><cell>FPGS</cell><cell>p&lt;0.0004</cell><cell>1.00</cell></row><row><cell>TYMS</cell><cell>p=0.0200</cell><cell>0.99</cell></row><row><cell>ERCC1</cell><cell>p=0.0082</cell><cell>1.00</cell></row><row><cell>MLH1</cell><cell>p&lt;0.0040</cell><cell>1.00</cell></row><row><cell>XRCC1</cell><cell>p=0.0263</cell><cell>1.00</cell></row><row><cell>FOLR1/TYMS Ratio</cell><cell>p&lt;0.0040</cell><cell>1.03</cell></row><row><cell>FOLR1/SLC19A1 Ratio</cell><cell>p=0.0017</cell><cell>1.05</cell></row><row><cell>FPGS/TYMS Ratio</cell><cell>p&lt;0.0001</cell><cell>2.54</cell></row><row><cell>Data for 11 patients (8 events)</cell><cell></cell><cell></cell></row><row><cell>FOLR1</cell><cell>p=0.0049</cell><cell>0.99</cell></row><row><cell>ERCC1</cell><cell>p=0.0026</cell><cell>0.99</cell></row><row><cell>FOLR1/SLC19A1 Ratio</cell><cell>p=0.0223</cell><cell>0.69</cell></row><row><cell>FOLR1/TYMS Ratio</cell><cell>p=0.0200</cell><cell>0.26</cell></row><row><cell>FPGS/TYMS Ratio</cell><cell>p=0.0225</cell><cell>&lt;0.01</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">www.impactjournals.com/oncotarget</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>We thank the nCounter Core Facility Heidelberg for providing the nCounter system and related services.</s></p><p><s>We thank the yWorks GmbH for providing the yEd Graph Editor that was used to produce Figure <ref type="figure">1</ref> (http:// www.yworks.com/yed).</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICTS OF INTEREST</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Editorial note</head><p><s>This paper has been accepted based in part on peerreview conducted by another journal and the authors' response and revisions as well as expedited peer-review in Oncotarget.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">CA: a cancer journal for clinicians</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Torre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lortet-Tieulent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jemal</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012. 2015</date>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="87" to="108" />
		</imprint>
	</monogr>
	<note>Global cancer statistics</note>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Neuroendocrine tumors of the lung: an update. Archives of pathology &amp; laboratory medicine</title>
		<author>
			<persName><forename type="first">N</forename><surname>Rekhtman</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010">2010</date>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="1628" to="1638" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Asamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kameya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Matsuno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Noguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yokose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakagawa</surname></persName>
		</author>
		<ptr target="www.impactjournals.com/oncotarget" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Neuroendocrine neoplasms of the lung: a prognostic spectrum</title>
		<author>
			<persName><forename type="first">K</forename><surname>Tajima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nagai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of clinical oncology</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="70" to="76" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Lung tumours with neuroendocrine differentiation</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Travis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European journal of cancer</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="251" to="266" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">International Agency for Research on Cancer., International Association for the Study of Lung Cancer and International Academy of Pathology</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Travis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">World</forename><surname>Health Organization</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2004">2004</date>
			<publisher>IARC Press Oxford University Press</publisher>
			<pubPlace>Lyon Oxford</pubPlace>
		</imprint>
	</monogr>
	<note>Pathology and genetics of tumours of the lung, pleura, thymus and heart</note>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. The Journal of thoracic and cardiovascular surgery</title>
		<author>
			<persName><forename type="first">H</forename><surname>Takei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Asamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maeshima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Niki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tsuchiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Matsuno</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2002">2002</date>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="285" to="292" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Swarts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Ramaekers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Speel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochimica et biophysica acta</title>
		<imprint>
			<biblScope unit="volume">1826</biblScope>
			<biblScope unit="page" from="255" to="271" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Reproducibility of neuroendocrine lung tumor classification</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Travis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Gal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">V</forename><surname>Colby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Klimstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Falk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Koss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Human pathology</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="272" to="279" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. The American journal of surgical pathology</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Travis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Rush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Flieder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Falk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Gal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Koss</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1998">1998</date>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="934" to="944" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</title>
		<author>
			<persName><forename type="first">S</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Adjei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gridelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kerr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Felip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Egw</forename><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annals of oncology</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="56" to="64" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall-cell lung cancer</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Scagliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Parikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Von Pawel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Biesma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vansteenkiste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Manegold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Serwatowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Gatzemeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Digumarti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zukin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mellemgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Patil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rolski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Goksel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of clinical oncology</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="3543" to="3551" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Gronberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bremnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Flotten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Amundsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Brunsvig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Hjelde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kaasa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Von Plessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Stornes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tollali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Aasebo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sundstrom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of clinical oncology</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="3217" to="3224" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">V</forename><surname>Monica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Scagliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ceppi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Righi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cambieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lo Iacono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saviozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Volante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Novello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Papotti</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung</title>
	</analytic>
	<monogr>
		<title level="j">Clinical cancer research</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="7547" to="7552" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous nonsmall cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Belani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Peterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Orlando</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of thoracic oncology</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="567" to="573" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ciuleanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Brodowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zielinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krzakowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Laack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Begbie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Tzekova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cucevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Pereira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Madhavan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Sugarman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Peterson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page" from="1432" to="1440" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bearz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Garassino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cavina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Favaretto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boccalon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Talamini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Berretta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Spazzapan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Simonelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santoro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Tirelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung cancer</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="240" to="245" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title level="m" type="main">Molecular basis of antifolate resistance. Cancer metastasis reviews</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">G</forename><surname>Assaraf</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2007">2007</date>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="153" to="181" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Pharmacology and mechanism of action of pemetrexed</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Adjei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical lung cancer</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="S51" to="55" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines</title>
		<author>
			<persName><forename type="first">E</forename><surname>Liani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rothem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Bunni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Jansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">G</forename><surname>Assaraf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International journal of cancer</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="587" to="599" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Adjei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="4276" to="4280" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Christoph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Asuncion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mascaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Wynes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Gauler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wohlschlaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Theegarten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Neumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Welter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stamatis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tannapfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schuler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Eberhardt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of thoracic oncology</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1440" to="1448" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients</title>
		<author>
			<persName><forename type="first">C</forename><surname>Camps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sarries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Roig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Queralt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sancho</forename><forename type="middle">E</forename><surname>Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Taron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rosell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical lung cancer</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="237" to="241" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">Nucleotide excision repair pathways involved in www</title>
		<author>
			<persName><forename type="first">R</forename><surname>Rosell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Taron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barnadas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Scagliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sarries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Roig</surname></persName>
		</author>
		<ptr target=".impactjournals.com/oncotarget" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Cisplatin resistance in non-small-cell lung cancer</title>
	</analytic>
	<monogr>
		<title level="j">Cancer control</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="297" to="305" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Hubner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Riley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Billingham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Popat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PloS one</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e25164</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Personalized medicine for lung cancer: new challenges for pathology</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Kerr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Histopathology</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="531" to="546" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Fouret P and International Adjuvant Lung Trial-Bio i. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Kamal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Soria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mendiboure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Planchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Olaussen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rousseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Popper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pirker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bertrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dunant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Chevalier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Filipits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical cancer research</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1206" to="1215" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cobo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Isla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Massuti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Montes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Provencio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Vinolas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Paz-Ares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lopez-Vivanco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Munoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Felip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Alberola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Camps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Domine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sanchez-Ronco</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of clinical oncology</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="2747" to="2754" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Differences in the expression profiles of excision repair crosscomplementation group 1, x-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jheon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of thoracic oncology</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="1307" to="1312" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum-and taxane-based neoadjuvant chemotherapy and surgical resection</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jheon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung cancer</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="478" to="483" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m" type="main">DNA repair deficiency as a therapeutic target in cancer. Current opinion in genetics &amp; development</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Lord</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ashworth</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="80" to="86" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mccabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mullarkey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cummins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Burgess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakabeppu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Oka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Lord</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ashworth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer cell</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="235" to="248" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinumbased chemotherapy in malignant pleural mesothelioma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Mairinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Welter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Eberhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wohlschlaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Christoph</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical lung cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="558" to="567" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Lo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Hsiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Jou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Hsiung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung cancer</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="280" to="286" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas</title>
		<author>
			<persName><forename type="first">D</forename><surname>Vageli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Daniil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dahabreh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Karagianni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Vamvakopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Ioannou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Scarpinato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Vamvakopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">I</forename><surname>Gourgoulianis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Koukoulis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung cancer</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="282" to="288" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Direct multiplexed measurement of gene expression with color-coded probe pairs</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Geiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Bumgarner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Birditt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Dahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Dowidar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Dunaway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Fell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ferree</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Grogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maysuria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Mitton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Oliveri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Osborn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Peng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature biotechnology</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="317" to="325" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vollbrecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Theegarten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Christoph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wohlschlaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Mairinger</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.3992</idno>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data</title>
		<author>
			<persName><forename type="first">D</forename><surname>Waggott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Wouters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">F</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Boutros</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1546" to="1548" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">FFPE tissue as a feasible source for gene expression analysis-a comparison of three reference genes and one tumor marker. Pathology, research and practice</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Mairinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wohlschlaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vollbrecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hager</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="volume">209</biblScope>
			<biblScope unit="page" from="784" to="789" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString)</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Mairinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vollbrecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Theegarten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Christoph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zarogoulidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zarogoulidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wohlschlaeger</surname></persName>
		</author>
		<author>
			<persName><surname>Sox4</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Future oncology</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1027" to="1036" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">The new lung cancer staging system</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Detterbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Boffa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Tanoue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="260" to="271" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Mairinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Christoph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vollbrecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zarogoulidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wohlschlaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zarogoulidis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Cancer</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="465" to="471" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Mairinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Theegarten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vollbrecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Christoph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stamatis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mairinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Baba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zarogoulidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tsakiridis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Cancer</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="646" to="654" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vandesompele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Preter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pattyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Poppe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van Roy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Paepe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Speleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome biology</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">H0034</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">New antilung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Franklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Waintrub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Prendegrast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Woods</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Bunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Kolhouse</surname></persName>
		</author>
		<ptr target="www.impactjournals.com/oncotarget44" />
	</analytic>
	<monogr>
		<title level="j">International journal of cancer Supplement</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="89" to="95" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>O'shannessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Smale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Singhal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Somers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vachani</surname></persName>
		</author>
		<idno>doi: 10.18632/ oncotarget.489</idno>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="414" to="425" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Christoph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Asuncion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Maltzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>O'shannessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Wynes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Gauler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wohlschlaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hoiczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schuler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Eberhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Hirsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of thoracic oncology</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="19" to="30" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Assessment of folate receptor-alpha and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Christoph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Reyna-Asuncion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Maltzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>O'shannessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Gauler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wohlschlaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schuler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Eberhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Hirsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical lung cancer</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="320" to="330" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: in biological properties compared to epithelial carcinoma</title>
		<author>
			<persName><forename type="first">T</forename><surname>Nagasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tsuchiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Honda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yamasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miyazaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hidaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nagayasu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical lung cancer</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="412" to="422" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Significance of thymidylate synthase for resistance to pemetrexed in lung cancer</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ozasa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Oguri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Uemura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Miyazaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Maeno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ueda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer science</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="161" to="166" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action</title>
		<author>
			<persName><forename type="first">M</forename><surname>Joerger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Omlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cerny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fruh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current drug targets</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="37" to="47" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ceppi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Volante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saviozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Rapa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Novello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cambieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lo Iacono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cappia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Papotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Scagliotti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="1589" to="1596" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies</title>
		<author>
			<persName><forename type="first">G</forename><surname>Scagliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fossella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sugarman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Blatter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Peterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Simms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Shepherd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The oncologist</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="253" to="263" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Smit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Socinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Mullaney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Myrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Scagliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lorigan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ciuleanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Von Pawel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Karaseva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Szczesna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ohannesian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Hozak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Guba</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annals of oncology</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1723" to="1729" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensivestage small-cell lung cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Socinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Smit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lorigan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Konduri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Szczesna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Blakely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Serwatowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Karaseva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ciuleanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jassem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dediu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Visseren-Grul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Hanauske</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Obasaju</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of clinical oncology</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="4787" to="4792" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Folate receptor-alpha (FOLR1) expression and function in triple negative tumors</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Necela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Crozier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Andorfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lewis-Tuffin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kachergus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Geiger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Kalari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Serie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Aspita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>O'shannessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Maltzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Mccullough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Pockaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Ballman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PloS one</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0122209</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">D</forename><surname>Horsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sayeg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kaemmerer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Presselt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Baum</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Pneumologie</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="44" to="48" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Kohonen-Corish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Kwun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mccaughan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kennedy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Sutherland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Histopathology</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="613" to="622" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Loss of DNA mismatch repair in acquired resistance to cisplatin</title>
		<author>
			<persName><forename type="first">S</forename><surname>Aebi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kurdi-Haidar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cenni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Christen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Boland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Koi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fishel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Howell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer research</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="3087" to="3090" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">The role of DNA mismatch repair in platinum drug resistance</title>
		<author>
			<persName><forename type="first">D</forename><surname>Fink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Aebi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cenni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nehme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Christen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Howell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer research</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="4881" to="4886" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Kamel-Reid S. mRNA transcript quantification in archival samples using multiplexed, color-coded probes</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Reis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Waldron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Goswami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Perez-Ordonez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gullane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Irish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Jurisica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC biotechnology</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">46</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">ERCC1 isoform expression and DNA repair in non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">L</forename><surname>Friboulet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Olaussen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pignon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Shepherd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Tsao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Graziano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kratzke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Douillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Seymour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pirker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Filipits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Andre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Solary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ponsonnailles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Robin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stoclin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The New England journal of medicine</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="1101" to="1110" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens</title>
		<author>
			<persName><forename type="first">T</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wallden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schaper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ferree</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Barry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Dowidar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maysuria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Storhoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">177</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
